You are here

Study: Increased Risk of Kidney Failure, Heart Attack, and Stroke Reported With Aprotinin in Cardiac Surgery

January 26, 2006 -- San Bruno, CA -- Aprotinin (Trasylol), a widely used heart-surgery medication that is standard therapy in many hospitals, has been found to carry increased risk of kidney failure, heart attacks, and strokes as compared with patients taking alternative drugs or no drugs at all. Researchers at the Ischemia Research and Education Foundation in San Bruno, CA, also examined alternatives and found them to be just as effective in limiting blood loss but didn't cause any of the dangerous side effects associated with Trasylol.

Trasylol has been approved since 1993 and it is given to about a quarter of the million people worldwide who undergo bypass surgery each year, the study's author estimates.

To read the study abstract, visit the New England Journal of Medicine's Web site and read the accompany editorial.

Bayer, the manufacturer of Trasylol, has issued a statement, available on the company's Web site.

Sources: New England Journal of Medicine

Recent Headlines

Scenesse is new treatment for people with rare, painful light sensitivity disease
Humira, Rituxan top list of drugs that added $5.1 billion to nation's health care bill
Lower court rulings cleared the way for generic versions of the MS drug
Maryland man wins lawsuit that alleges that the company's antipsychotic caused his gynecomastia
Antidepressants, ADHD meds are also used to self-poison
Study lists steps that could save close to $300 billion a year
While many victims used THC, the cause remains elusive
Descovy joins Truvada, another Gilead product, in the HIV prophylaxis market
Data show PTC Therapeutics drug preserves lung function